0.571

0.33% -0.0019

Pre-market: .59 0.019 +3.33%

Intensity Therapeutics Inc (INTS)

Overview News Price History Financials Why INTS Down? Discussions Forecast

Intensity Therapeutics Inc stock is traded at $0.571, with a volume of 141.07K. It is down -0.33% in the last 24 hours and down -70.41% over the past month. Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.

Previous Close:

$0.5729

Open:

$0.5557

24h Volume:

141.07K

Relative Volume:

1.19

Market Cap:

$9.72M

Revenue:

Net Income/Loss:

$-16.26M

P/E Ratio:

-0.4833

EPS:

-1.1814

Net Cash Flow:

$-13.50M

1W Performance:

-10.35%

1M Performance:

-70.41%

6M Performance:

-82.10%

1Y Performance:

-85.21%

1-Day Range:

$0.55

$0.58

1-Week Range:

$0.5428

$0.6365

52-Week Range:

$0.50

$5.275

Intensity Therapeutics Inc Stock (INTS) Company Profile

Name

Intensity Therapeutics Inc

Sector

Healthcare (1150)

Industry

Biotechnology (676)

Phone

203-221-7381

Address

1 ENTERPRISE DRIVE, SUITE 430, SHELTON

Employee

Twitter

Next Earnings Date

Latest SEC Filings

INTS's Discussions on Twitter

Compare INTS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
INTS Intensity Therapeutics Inc	0.571	9.72M	0	-16.26M	-13.50M	-1.1814
VRTX Vertex Pharmaceuticals Inc	500.19	127.64B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	603.58	65.95B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	656.65	37.92B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	273.55	32.98B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	254.16	26.92B	3.81B	-644.79M	-669.77M	-6.24

Intensity Therapeutics Inc Stock (INTS) Latest News

May 05, 2025

Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, - openPR.com

May 05, 2025

Cholangiocarcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com

May 05, 2025

May 02, 2025

Offerings News Live Feed - Stock Titan

May 02, 2025

Intensity Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds - Barchart.com

May 02, 2025

Apr 29, 2025

Intratumoral Cancer Therapies Market Predicted to See Upsurge - openPR.com

Apr 29, 2025

Post-Trade Analysis: Intensity Therapeutics Inc (INTS) Climbs 12.57, Closing at 0.64 - DWinneX

Apr 29, 2025

Daily Market Movement: Lexeo Therapeutics Inc (LXEO) Sees a -3.53 Decrease, Closing at 3.55 - DWinneX

Apr 29, 2025

Closing Bell Recap: Greenlane Holdings Inc (GNLN) Ends at 0.01, Reflecting a -3.23 Downturn - DWinneX

Apr 29, 2025

In the Green: TMD Energy Ltd (TMDE) Closes at 1.58, Up/Down 5.33 from Previous Day - DWinneX

Apr 29, 2025

Apr 28, 2025

Navigating INTS’s Stock Market Maze: Ups and Downs in 2023 - investchronicle.com

Apr 28, 2025

The Business Case For Buying Intensity Therapeutics Inc (NASDAQ: INTS) Stock Now - Stocksregister

Apr 28, 2025

Apr 26, 2025

Intensity Therapeutics plunges on $2.35M public offering - MSN

Apr 26, 2025

Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail

Apr 26, 2025

US Stock Futures Dip As Oil Prices Continue To Slide - Finimize

Apr 26, 2025

Apr 25, 2025

United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India

Apr 25, 2025

U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com

Apr 25, 2025

Intensity Therapeutics sets terms for $2.35 million offering - Investing.com

Apr 25, 2025

Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal

Apr 25, 2025

Intensity Therapeutics (INTS) Launches Public Offering to Raise $2.35 Million | INTS Stock News - GuruFocus

Apr 25, 2025

Why Intensity Therapeutics (INTS) Stock Is Getting Hammered - Benzinga

Apr 25, 2025

Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire

Apr 25, 2025

Apr 24, 2025

Low-intensity transcranial focused ultrasound amygdala neuromodulation: a double-blind sham-controlled target engagement study and unblinded single-arm clinical trial - Nature

Apr 24, 2025